Patients with poorly controlled type 2 diabetes despite being on dulaglutide had better outcomes if they switched to tirzepatide than if they upped their dulaglutide dose. In this randomized trial, ...

Switching to tirzepatide linked to additional reduction in HbA1c, weight loss compared with escalating dulaglutide. (HealthDay News) — For patients with inadequately controlled type 2 diabetes ...

NEW ORLEANS — For people with type 2 diabetes (T2D) inadequately controlled on submaximal dulaglutide (Trulicity) doses, switching to tirzepatide (Mounjaro) produces significantly greater A1c and ...

Please provide your email address to receive an email when new articles are posted on . Adults with type 2 diabetes had larger decreases in HbA1c at 28 weeks with mazdutide vs. dulaglutide. More than ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide is approved by the FDA for slowing the progression of chronic kidney disease. Liraglutide and ...

VIENNA — Tirzepatide (Mounjaro) is cardioprotective in people with type 2 diabetes (T2D) and established atherosclerotic cardiovascular (CV) disease, but not more so than dulaglutide (Trulicity), ...

Diabetes patients on dulaglutide (Trulicity) had better glycemic control and more weight loss if they switched to tirzepatide (Mounjaro) rather than increasing the dose of the earlier-generation GLP-1 ...